Compile Data Set for Download or QSAR
Report error Found 73 of affinity data for UniProtKB/TrEMBL: Q72502
TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271430(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271439(4- (((3aS,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((R)...)
Affinity DataEC50:  3.08E+3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271438(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  120nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271437(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((R)...)
Affinity DataEC50:  5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271436(5- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  213nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271435(4- {[(1R,2R,10S,13R,14R, 17S,19R)-5-[(5R)-3-[1-(5-...)
Affinity DataEC50:  1.00E+4nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271434(4- {[(1R,2R,10S,13R,14R, 17S,19R)-5-[(5S)-3-[1-(5-...)
Affinity DataEC50:  8.41E+3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271433(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- (c...)
Affinity DataEC50:  17.2nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271432(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-1- hy...)
Affinity DataEC50:  379nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271431(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  8nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271440(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a-(2- (...)
Affinity DataEC50:  16.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271429(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  494nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271428(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-1- (a...)
Affinity DataEC50:  7nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271427(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  6.30nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271426(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  1.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271425(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((R)...)
Affinity DataEC50:  192nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271424(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2-{N-...)
Affinity DataEC50:  72.9nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271423(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2-{N-...)
Affinity DataEC50:  64.8nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271422(4- (((3aR,5aR,5bR,7aR, 9S,11aR,11bR,13aS)- 3a-((R)...)
Affinity DataEC50:  2.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271449(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {b...)
Affinity DataEC50:  1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271457(2,2-dimethyl-4-oxo-4- {[(1R,2R,5R,10S,13R,14R, 17S...)
Affinity DataEC50:  144nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271456(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(2- ch...)
Affinity DataEC50:  70.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271455(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2-[1-...)
Affinity DataEC50:  5.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271454(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  2.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271453(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  76.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271452(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  2.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271451(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271450(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.900nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271421(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  2.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271448(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  4.80nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271447(5- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  62.3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271446(5- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  10.8nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271445(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-1- (a...)
Affinity DataEC50:  35.3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271444(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-1- (a...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271443(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  4.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271442(4- (((3aR,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  110nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271441(4- (((3aS,5aR,5bR,7aR,9S, 11aR,11bR,13aS)-3a- ((S)...)
Affinity DataEC50:  411nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271393(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  2.40nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271401(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  0.700nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271400(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-1- (a...)
Affinity DataEC50:  29.2nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271399(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  7.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271398(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  31.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271397(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1R)-2- {[...)
Affinity DataEC50:  3.60nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271396(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{N-[(4- ...)
Affinity DataEC50:  2.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271395(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(4- ch...)
Affinity DataEC50:  5.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271394(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[1-(4- ...)
Affinity DataEC50:  6.70nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271402(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-[(1S)-2- {[...)
Affinity DataEC50:  4.10nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271392(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[1-(4- ...)
Affinity DataEC50:  13.5nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271391(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(3- ch...)
Affinity DataEC50:  14.3nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

TargetEnvelope glycoprotein gp160 [V370A](Human immunodeficiency virus type 1)
Glaxosmithkline

US Patent
LigandPNGBDBM271390(4- {[(1R,2R,5R,10S,13R,14R, 17S,19R)-5-(2-{[(3- ch...)
Affinity DataEC50:  23.1nMAssay Description:Antiviral HIV activity and compound-induced cytotoxicity were measured in parallel by means of a propidium iodide based procedure in the human T-cell...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
US Patent

Displayed 1 to 50 (of 73 total ) | Next | Last >>
Jump to: